Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Further analysis of Phase III COMFORT™ data show Piclidenoson’s superior safety profile and higher patient compliance compared to Otezla® PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that it is planning to … [Read more…]

Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. “We are thrilled to welcome Dr. Ryder to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer. “He is joining us … [Read more…]

Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/. This report is prepared based on the revised Corporate Governance Code as … [Read more…]

Global Orphan Cancer Drug Market Report 2022-2028: Featuring Key Players Pfizer, GlaxoSmithKline, Bristol Myers Squibb & Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028” report has been added to ResearchAndMarkets.com’s offering. Orphan cancer drugs are novel pharmaceuticals that are indicated for the prevention, diagnosis, or treatment of rare cancers. These rare cancers are chronic and life-threatening which require proper long-term medications. As these diseases … [Read more…]

NanoString to Release Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022

SEATTLE–(BUSINESS WIRE)–#earnings–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report second quarter 2022 operating results after the close of the market on Thursday, August 4, 2022. Company management will host a conference call beginning at 4:30pm ET to discuss those results … [Read more…]

Axonics® to Report Second Quarter 2022 Financial Results on August 1

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss … [Read more…]

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Three Labs in Japan and Spain to Receive Novel Compact Ascend Evo 1.0 GHz Magnets UTRECHT, The Netherlands–(BUSINESS WIRE)–$BRKR #BRKR–At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend … [Read more…]

Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Community-Acquired Bacterial Pneumonia (CABP) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, … [Read more…]

New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A

– Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mild hemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up – – New data also reinforce Hemlibra’s favorable safety profile, with no new safety signals observed – – There is limited information and treatment guidance on moderate … [Read more…]

Thermo Fisher Scientific Launches CE-IVD Marked TaqPath Respiratory Viral Select Panel

The PCR assay panel tests for five respiratory viruses in under three hours CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Applied Biosystems TaqPath Respiratory Viral Select Panel; a CE-IVD-marked molecular assay panel for detection of five common viruses, including those that cause the common cold, … [Read more…]